Similar parameters of safety and tolerability were also assessed for the cell-penetrating enhancing agent INT230-6 as monotherapy (phase I) and in combination with α-PD-1 and α-CTLA-4 mAbs (phase II) for CH. The gene discussed is CTLA4; the disease is cyclic hematopoiesis.